Reuters UK (Free subscription) | yesterday
LONDON (Reuters) - The world's two biggest drugmakers, Pfizer and GlaxoSmithKline , both beat expectations for quarterly earnings on Wednesday, as did Wyeth , indicating the sector's resilience.
Public Blog (Free subscription) | yesterday
Washington's largest lobby, the pharmaceutical industry, had a very successful year backed by a record $168 million lobbying effort. Among the industry's successes were getting two controversial laws extended, and thwarting congressional efforts to restrict media ads for prescription drugs. The spending represents a 32 percent jump over 2006 numbers, driven in part by a busy legislative calendar dominated...
The Earth Times Online Newspaper (Free subscription) | yesterday
LONDON (Reuters) - The world's two biggest drugmakers, Pfizer Inc and GlaxoSmithKline Plc , both beat expectations for quarterly earnings on Wednesday, as did Wyeth , indicating the sector's resilience.
Reuters (Free subscription) | yesterday
LONDON (Reuters) - The world's two biggest drugmakers, Pfizer Inc and GlaxoSmithKline Plc , both beat expectations for quarterly earnings on Wednesday, as did Wyeth , indicating the sector's resilience.
New York Times (Free subscription) | yesterday
Biogen Idec reported a higher-than-expected second-quarter profit on Tuesday as sales of its closely watched multiple sclerosis drug Tysabri surged past Wall Street estimates.
Seattle Times (Free subscription) | yesterday
Bristol-Myers Squibb has agreed to pay the Washington state nearly $7 million to settle allegations of illegal marketing and pricing of prescription medications.
Life Science World (Free subscription) | 22/07/2008
[JOB] AstraZeneca, Sommerville, NJ, USA
The Independent (Free subscription) | 5 hours ago
GlaxoSmithKline's new chief executive signalled his intent to launch an expansion drive into the emerging markets yesterday as he revealed his strategic objectives for the first time and announced a "transformational" partnership with a South African drugs company.
The Street (Free subscription) | yesterday
Also, Pfizer tops estimates by a penny.
Scotsman.com (Free subscription) | 5 hours ago
GLAXOSMITHKLINE must change to survive the growing threat of generic competition for its leading products, its chief executive warned yesterday.
Financial Time (Free subscription) | 2 hours ago
Pfizer yesterday reported that its second quarter earnings had more than doubled on higher sales of its prescription drugs and with lower expenses. In a conference...
The Herald (Free subscription) | 6 hours ago
GlaxoSmithkline, the world’s second-largest drug maker, posted a 3% fall in second-quarter net profit yesterday after strong competition from generic drugs outweighed asset sales and the cost-saving effects of job cuts.
Law Blog - WSJ.com (Free subscription) | yesterday
GlaxoSmithKline will make additional changes to its drug-research team and work with a company that sells low-cost medicines in emerging markets. The U.K. drug giant posted weak second-quarter results.
Financial Time (Free subscription) | 2 hours ago
GlaxoSmithKline's shift into generic drugs by means of its partnership with Aspen reflects and develops a trend during recent years by large pharmaceutical companies...
The Telegraph India (Free subscription) | 5 hours ago
Mumbai, July 23: GlaxoSmithKline has entered into an alliance with Onco Therapies Ltd, a joint venture of Strides Arcolab, in branded generics.
